What happens when approved drugs turn out not to work? Is it OK to make SARS-CoV-2 hybrids? And are British tabloids reliable sources of science news?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Lawyer and bioethicist Holly Fernandez Lynch joins us to explain a watershed test of the FDA’s authority to revoke drug approvals. And STAT’s Helen Branswell calls in to discuss the headline-grabbing research at Boston University involving a lab-developed version of the virus that causes Covid-19.
With mRNA’s exciting therapeutic potential, biopharma prepares to drive vital progress
The convergence of mRNA and other advances like CRISPR, immuno-oncology, and intracellular antibodies has created a perfect storm that can change the course of medicine. Now, with the scientific community closer than ever to realizing the power of many exciting areas of research, companies are preparing to support extraordinary progress in therapeutic development and clinical care. Scott Ripley, general manager of nucleic acid therapeutics at Cytiva, tells us more.
No comments